The hosting structure
The Curie Institute Research Center
The “Institut Curie” is a major player in the research and fight against cancer. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.
In the Research Center, the CurieCoreTech - Core Facilities include among others an experimental radiotherapy platform (https://curie.fr/plateforme/curiecoretech-radiotherapie-experimentale-radexp) and an experimental electron Flash (7 MeV) machine. The Hospital facilities include equipment supporting proton Flash and minibeam radiation therapy. In addition, a new experimental very high energy electron Flash platform is currently being developed (FRATHEA2024 project supported by France 2030 and Région Ile de France “grand projet d’innovation”) which will allow the combination of Flash and minibeam radiation therapy.
The project leader will join a research team that includes about 20 people developing advanced therapy in radiation oncology within a research lab of about 65 with expertise in molecular imaging, digital pathology, preclinical testing, radiomics and dosiomics.
Job description
The medical-scientific program entitled “Innovative radiotherapy, radiobiology and molecular imaging”, which is the embodiment of the research-care continuum that makes the Institut Curie model so unique, coordinates the joint efforts of the Research Center and the Hospital Group to strengthen our contribution to the fight against cancer at the national and international level. The close integration between cutting-edge research and patient care provides an exceptional environment for impactful cancer research, fostering innovations that can directly benefit patients.
The translational radiation oncology program is a flagship program of Institut Curie medical-scientific program and the project leader is expected to play a key role in that program.
Job description
The Project Leader goal is to actively :
- Contribute to the development of innovative fractionated radiotherapy regimens,
- Participate in the investigation of the associated radiobiological mechanisms,
- Study their interplay with biological mechanisms associated with other treatment modalities such as immunotherapy,
- Design preclinical and clinical trials aiming at demonstrating the value of innovative dose delivery approaches. Applicants are expected to propose an ambitious research program along these lines.
Training and experience required
- PhD and at least one postdoc experience
- Excellent track record (publications, grants)
- Fluent in English
- Previous experience in management would be a bonus but is not mandatory
All our opportunities are open to people with disabilities
Contract information
Type of contract: Fixed-term contract with a defined objective / 36 months maximum
Starting date: as soon as possible
Working time: full time
Remuneration: according to candidate experience
Benefits: Collective catering, reimbursement of transportation fees up to 70%, supplementary health insurance
Location of the position: Orsay (91)
Reference: not to be completed
A package that will match the expertise of the candidate will be provided to support the start of the project.
This package is supported by the SIRIC Curie « INCa-DGOS-Inserm-ITMO cancer_18000 » and is also open to candidates with an existing post (Inserm, CNRS...).
Contact
To apply for this position, candidates should provide a cover letter explaining their interest in joining the Institut Curie, a curriculum vitae, a summary of scientific achievements (1 page), a proposed research program (3 pages) and 2-3 references.
Applications should be sent as a single PDF to job-ref-gss79ms3lu@emploi.beetween.com
Publication date: not to be completed
Deadline for application: 28 February 2025
Institut Curie is an inclusive, equal opportunity employer
and is dedicated to the highest standards of research integrity.
https://euraxess.ec.europa.eu/sites/default/files/brochures/eur_21620_en-fr.pdf